Tian An Medicare Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Tian An Medicare.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth	17.0%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

China Medical & HealthCare Group's (HKG:383) Returns On Capital Not Reflecting Well On The Business

Feb 02

Returns On Capital Signal Difficult Times Ahead For China Medical & HealthCare Group (HKG:383)

Oct 26

Is China Medical & HealthCare Group (HKG:383) Using Debt In A Risky Way?

Sep 30

China Medical & HealthCare Group (HKG:383) Might Have The Makings Of A Multi-Bagger

Dec 10

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tian An Medicare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:383 - Analysts future estimates and past financials data (HKD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	1,569	11	160	356	N/A
9/30/2023	1,516	-35	112	277	N/A
6/30/2023	1,463	-81	4	138	N/A
3/31/2023	1,450	-103	-61	75	N/A
12/31/2022	1,438	-124	-68	70	N/A
9/30/2022	1,464	-115	-18	120	N/A
6/30/2022	1,491	-107	31	169	N/A
3/31/2022	1,477	-122	48	194	N/A
12/31/2021	1,463	-137	65	219	N/A
9/30/2021	1,447	-127	36	176	N/A
6/30/2021	1,430	-116	7	133	N/A
3/31/2021	1,312	-114	-55	59	N/A
12/31/2020	1,194	-112	-116	-16	N/A
6/30/2020	1,099	-81	-109	32	N/A
3/31/2020	1,163	-40	-14	104	N/A
12/31/2019	1,228	1	81	176	N/A
6/30/2019	1,196	35	-95	-51	N/A
3/31/2019	1,168	-8	272	327	N/A
12/31/2018	1,139	-52	639	705	N/A
9/30/2018	1,120	-94	776	839	N/A
6/30/2018	1,101	-137	913	973	N/A
3/31/2018	1,115	-198	419	495	N/A
12/31/2017	1,130	-258	-75	16	N/A
9/30/2017	1,207	-165	N/A	100	N/A
6/30/2017	1,284	-72	N/A	184	N/A
3/31/2017	1,791	-143	N/A	296	N/A
12/31/2016	2,297	-214	N/A	408	N/A
9/30/2016	2,349	-498	N/A	88	N/A
6/30/2016	2,400	-783	N/A	-232	N/A
3/31/2016	1,787	-375	N/A	N/A	N/A
12/31/2015	1,175	33	N/A	37	N/A
9/30/2015	945	131	N/A	325	N/A
6/30/2015	715	228	N/A	613	N/A
3/31/2015	859	233	N/A	N/A	N/A
12/31/2014	1,003	237	N/A	926	N/A
9/30/2014	1,050	582	N/A	480	N/A
6/30/2014	1,096	928	N/A	34	N/A
12/31/2013	219	-363	N/A	-580	N/A
9/30/2013	80	-541	N/A	-29	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 383's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if 383's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 383's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 383's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 383's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 383's Return on Equity is forecast to be high in 3 years time

Tian An Medicare Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

China Medical & Healthcare Group Limited Provides Earnings Guidance for Eleven Months Ended 30 November 2023

China Medical & HealthCare Group Limited Provides Group Earnings Guidance for the Five Months Ended 31 May 2023

China Medical & Healthcare Group Limited Provides Consolidated Earnings Guidance for the Eleven Months Ended 30 November 2022

China Medical & HealthCare Group Limited Provides Unaudited Consolidated for the Five Months Ended 31 May 2022

China Medical & HealthCare Group Limited Provides Unaudited Consolidated Earnings Guidance for the Four Months Ended April 30, 2021

Recent updates

Upcoming dividend of HK$0.01 per share

Full year 2023 earnings released: EPS: HK$0.012 (vs HK$0.17 loss in FY 2022)

China Medical & Healthcare Group Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 02 August 2024

Full year 2023 earnings released: EPS: HK$0.012 (vs HK$0.17 loss in FY 2022)

China Medical & HealthCare Group Limited, Annual General Meeting, May 20, 2024

China Medical & HealthCare Group Limited to Report Fiscal Year 2023 Final Results on Mar 15, 2024

New minor risk - Market cap size

China Medical & Healthcare Group Limited Provides Earnings Guidance for Eleven Months Ended 30 November 2023

China Medical & Healthcare Group Limited Announces Company Secretary and Authorised Representative Changes

China Medical & HealthCare Group Limited Announces Change in the Composition of the Board of Directors and Change of Members of the Board Committees

Tian An China Investments Company Limited (SEHK:28) completed the acquisition of 18.13% stake in China Medical & HealthCare Group Limited (SEHK:383) from its shareholders for approximately HKD 180 million.

China Medical & Healthcare Group Limited Announces Resignation of Chong Sok Un as Executive Director and Deputy Chairman and Change in Composition of the Board Committees

First half 2023 earnings released: HK$0.002 loss per share (vs HK$0.061 loss in 1H 2022)

New major risk - Revenue and earnings growth

China Medical & HealthCare Group Limited to Report Second Half, 2023 Results on Aug 18, 2023

China Medical & HealthCare Group Limited Provides Group Earnings Guidance for the Five Months Ended 31 May 2023

Full year 2022 earnings released: HK$0.17 loss per share (vs HK$0.19 loss in FY 2021)

China Medical & HealthCare Group's (HKG:383) Returns On Capital Not Reflecting Well On The Business

China Medical & Healthcare Group Limited Provides Consolidated Earnings Guidance for the Eleven Months Ended 30 November 2022

Less than half of directors are independent

China Medical & Healthcare Group Limited Announces Executive Changes

Returns On Capital Signal Difficult Times Ahead For China Medical & HealthCare Group (HKG:383)

Is China Medical & HealthCare Group (HKG:383) Using Debt In A Risky Way?

First half 2022 earnings released: HK$0.003 loss per share (vs HK$0.005 loss in 1H 2021)

China Medical & HealthCare Group Limited Provides Unaudited Consolidated for the Five Months Ended 31 May 2022

Less than half of directors are independent

Full year 2021 earnings released: HK$0.009 loss per share (vs HK$0.008 loss in FY 2020)

China Medical & HealthCare Group Limited, Annual General Meeting, Jun 01, 2022

China Medical & HealthCare Group (HKG:383) Might Have The Makings Of A Multi-Bagger

First half 2021 earnings released: HK$0.005 loss per share (vs HK$0.005 loss in 1H 2020)

First half 2021 earnings released: HK$0.005 loss per share (vs HK$0.005 loss in 1H 2020)

China Medical & HealthCare Group Limited Provides Unaudited Consolidated Earnings Guidance for the Four Months Ended April 30, 2021

Executive Director has left the company

Non-Executive Director has left the company

Chairman Liye Zhou has left the company

We Think China Medical & HealthCare Group (HKG:383) Has A Fair Chunk Of Debt

China Medical & HealthCare Group Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Do Institutions Own China Medical & HealthCare Group Limited (HKG:383) Shares?

Is China Medical & HealthCare Group (HKG:383) A Risky Investment?

China Medical & Healthcare Group Limited Appoints Lai Hin Wing Henry Stephen as Non-Executive Director, Effective November 11, 2020

First half earnings released

China Medical & HealthCare Group Limited to Report 18 Months Period Ending Dec 31, 2019 Results on Mar 30, 2020

China Medical & HealthCare Group Limited to Report Second Half, 2020 Results on Aug 27, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies